JP2022510690A5 - - Google Patents

Info

Publication number
JP2022510690A5
JP2022510690A5 JP2021532071A JP2021532071A JP2022510690A5 JP 2022510690 A5 JP2022510690 A5 JP 2022510690A5 JP 2021532071 A JP2021532071 A JP 2021532071A JP 2021532071 A JP2021532071 A JP 2021532071A JP 2022510690 A5 JP2022510690 A5 JP 2022510690A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
group
aryl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021532071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022510690A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/064548 external-priority patent/WO2020117987A1/en
Publication of JP2022510690A publication Critical patent/JP2022510690A/ja
Publication of JP2022510690A5 publication Critical patent/JP2022510690A5/ja
Priority to JP2024199809A priority Critical patent/JP2025028061A/ja
Pending legal-status Critical Current

Links

JP2021532071A 2018-12-05 2019-12-04 肝障害の処置のための組成物及び方法 Pending JP2022510690A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024199809A JP2025028061A (ja) 2018-12-05 2024-11-15 肝障害の処置のための組成物及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862775799P 2018-12-05 2018-12-05
US62/775,799 2018-12-05
US201962821303P 2019-03-20 2019-03-20
US62/821,303 2019-03-20
PCT/US2019/064548 WO2020117987A1 (en) 2018-12-05 2019-12-04 Compositions and methods for the treatment of liver disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024199809A Division JP2025028061A (ja) 2018-12-05 2024-11-15 肝障害の処置のための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2022510690A JP2022510690A (ja) 2022-01-27
JP2022510690A5 true JP2022510690A5 (cg-RX-API-DMAC7.html) 2022-12-13

Family

ID=70974003

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021532071A Pending JP2022510690A (ja) 2018-12-05 2019-12-04 肝障害の処置のための組成物及び方法
JP2024199809A Pending JP2025028061A (ja) 2018-12-05 2024-11-15 肝障害の処置のための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024199809A Pending JP2025028061A (ja) 2018-12-05 2024-11-15 肝障害の処置のための組成物及び方法

Country Status (10)

Country Link
US (1) US20220016136A1 (cg-RX-API-DMAC7.html)
EP (1) EP3890748A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022510690A (cg-RX-API-DMAC7.html)
KR (1) KR20210099612A (cg-RX-API-DMAC7.html)
CN (1) CN113365637A (cg-RX-API-DMAC7.html)
AU (2) AU2019394947B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010916A2 (cg-RX-API-DMAC7.html)
CA (1) CA3121620A1 (cg-RX-API-DMAC7.html)
MX (5) MX2021006575A (cg-RX-API-DMAC7.html)
WO (1) WO2020117987A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
WO2018094265A2 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
EP4775207A2 (en) 2018-12-05 2026-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
CN112707892A (zh) * 2019-10-24 2021-04-27 苏州泽璟生物制药股份有限公司 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物
PT4097099T (pt) 2020-02-07 2024-07-19 Gasherbrum Bio Inc Agonistas heterocíclicos de glp-1
US11752161B2 (en) 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof
WO2021219019A1 (en) 2020-04-29 2021-11-04 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
EP4161925A4 (en) 2020-06-09 2024-09-04 Viking Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES
WO2021259309A1 (zh) * 2020-06-24 2021-12-30 广州市恒诺康医药科技有限公司 Glp-1受体激动剂及其药物组合物和用途
CN115093404B (zh) * 2020-07-17 2024-06-21 瀚海新拓(杭州)生物医药有限公司 苯并五元杂环磺酰胺类化合物、其制备方法、药物组合物及应用
PE20231181A1 (es) 2020-08-06 2023-08-11 Gasherbrum Bio Inc Agonistas del glp-1 heterociclicos
SI4408840T1 (sl) 2021-09-27 2025-12-31 Terns Pharmaceuticals, Inc. Benzimidazolne karboksilne kisline kot agonisti GLP-1R
EP4490155A1 (en) 2022-03-09 2025-01-15 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN121002014A (zh) 2022-12-15 2025-11-21 加舒布鲁姆生物公司 具有glp-1激动剂活性的化合物的盐和固体形式
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
WO2025193816A1 (en) * 2024-03-14 2025-09-18 Viking Therapeutics, Inc. Pharmaceutical compositions and methods for the treatment of metabolic and liver disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2428516A1 (en) * 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US20090232879A1 (en) * 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
MX2011011376A (es) * 2009-04-27 2012-04-20 Immuron Ltd Preparacion de inmunoglobulina enriquecida con anti-lps, para utilizarse en tratamiento y/o profilaxis de un trastorno patologico.
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
CA2871793C (en) * 2012-05-02 2020-09-15 Pharmaxis Ltd. Substituted 3-haloallylamine inhibitors of ssao and uses thereof
CA3058542A1 (en) * 2017-04-18 2018-10-25 Genfit Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
AU2018280118B2 (en) * 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EP4161925A4 (en) * 2020-06-09 2024-09-04 Viking Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES

Similar Documents

Publication Publication Date Title
JP7604666B2 (ja) 代謝及び肝臓障害の処置のための組成物及び方法
ES2836973T3 (es) Derivados de ácido carboxílico que comprenden cuatro ciclos que actúan como moduladores de receptor GLP-1 para la terapia de enfermedades tales como la diabetes
RU2569063C2 (ru) Конъюгаты жирных кислот и ниацина и их применение
ES2525429T3 (es) Inhibidores de la proteína tirosina fosfatasa humana y métodos de uso
ES2397664T3 (es) Derivados de glucopiranósilo que contienen tienilo como antidiabéticos
US20130190327A1 (en) Bis-fatty acid conjugates and their uses
WO2009038204A1 (ja) 新規長鎖脂肪酸誘導体化合物及びそれら化合物を有効成分とするgタンパク質共役型レセプター作動剤
RU2012128547A (ru) Дважды ацилированные производные glp-1
RU2003110577A (ru) Гетероциклические соединения, связывающиеся с хемокиновыми рецепторами
EA021174B1 (ru) Применение ингибиторов дипептидилпептидазы
KR20110013411A (ko) (f-19)-표지된 l-글루탐산 및 l-글루타민 유도체 (ⅲ), 그의 용도 및 그의 수득 방법
JP2024095711A (ja) 可溶性グアニル酸シクラーゼ活性化薬としてのアルコキシピラゾール
US20090074844A1 (en) Trenadermal absorption preparation
KR20250041009A (ko) 대사 및 간 장애 치료를 위한 조성물 및 방법
JP5014978B2 (ja) ヘテロ6員環化合物及びその用途
ES2202449T3 (es) Inhibidor de edema cerebral.
JP7812338B2 (ja) Glp受容体アゴニスト
TW202412761A (zh) 以ask1抑制劑治療器官疾病或病症的方法
US20040152753A1 (en) Methods of use for novel sulfur containing organic nitrate compounds
JP2008530242A5 (cg-RX-API-DMAC7.html)
JP7661969B2 (ja) 1,4,5,6-テトラヒドロピリミジン-2-アミン誘導体
JP2023553989A5 (cg-RX-API-DMAC7.html)
ES2890924T3 (es) Derivados de imidazol para el tratamiento de la hipertensión y/o la fibrosis
JP2009513606A (ja) β−3受容体アゴニストとして使うためのベンゾイミダゾール誘導体
RU2025110010A (ru) Фармацевтическая композиция двойного агониста рецепторов glp-1 и gip и ее применение